Welcome to our dedicated page for HEARTFLOW SEC filings (Ticker: HTFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Heartflow, Inc. (Nasdaq: HTFL), a medical technology company that applies artificial intelligence to coronary computed tomography angiography (CTA) for non-invasive coronary artery disease detection and management. Investors can review the company’s periodic and current reports to understand its financial condition, risk factors, and key operational developments.
Heartflow’s Form 10-K annual reports and Form 10-Q quarterly reports describe its business as a commercial-stage provider of non-invasive CAD detection solutions built around the Heartflow One platform, including FFRCT Analysis and Plaque Analysis. These filings typically discuss revenue sources, geographic operations in regions such as the United States, the United Kingdom, Japan, and the rest of Europe, and the company’s status as an emerging growth company listed on the Nasdaq Global Select Market.
Form 8-K current reports offer more immediate updates on material events, such as financial results releases, participation in financing transactions, or changes to credit agreements. For example, Heartflow has used Form 8-K to furnish earnings press releases and to disclose the prepayment and termination of a prior credit agreement following its initial public offering.
Through this page, users can also locate proxy statements and executive compensation disclosures, as well as Form 4 insider transaction reports when applicable. Stock Titan enhances these filings with AI-powered summaries that explain complex sections, highlight important risk disclosures, and clarify how Heartflow’s CAD-focused health information services and AI technologies are reflected in its regulatory reporting. Real-time updates from the SEC’s EDGAR system ensure that new HTFL filings, including 10-Ks, 10-Qs, 8-Ks, and ownership reports, are available promptly for detailed review.
Heartflow, Inc. disclosed that investment entities affiliated with Bain Capital Life Sciences, including BCLS Fund III Investments, LP, reported open-market sales of a combined 2,000,000 shares of Common Stock. The sales occurred on April 28–30, 2026 at weighted average prices generally between $29.00 and $31.46 per share.
The securities are held directly by BCLS Fund III Investments, LP, while related Bain Capital Life Sciences entities may be deemed to share voting and dispositive power and each disclaims beneficial ownership except to the extent of its pecuniary interest. After these transactions, the filing shows indirect holdings of up to 10,194,048 shares on the earliest reported date and 8,448,158 shares following the latest reported sale.
Heartflow, Inc. is asking stockholders to elect two Class I directors and ratify PricewaterhouseCoopers LLP as auditor at its 2026 annual meeting. The virtual-only meeting will be held on June 16, 2026 at 8:00 a.m. Pacific Time, with April 24, 2026 as the record date.
Seven directors serve on a classified board, and most are independent under Nasdaq rules. The proxy details 2025 director and executive pay, including stock option and RSU grants, a new clawback policy, anti-hedging rules, and a senior leadership severance policy tied to terminations and change in control.
Heartflow, Inc. Chief Executive Officer John C.M. Farquhar reported an open-market sale of 22,562 shares of Common Stock at $26.72 per share on April 10, 2026. After this trade, he directly holds 549,163 shares, indicating he retained the vast majority of his position.
The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, suggesting the transaction was scheduled in advance as part of a systematic trading program rather than a spur-of-the-moment decision.
HTFL affiliate filed a Form 144 to report proposed resale of 22,562 shares of Common Stock tied to a stock option exercise dated 06/25/2024. The filing also lists three dispositions by John C.M. Farquhar: 22,562 shares on 02/10/2026, 12,837 shares on 03/10/2026, and 9,725 shares on 03/18/2026, with proceeds shown for each transaction.
Heartflow, Inc. Chief Medical Officer Campbell Rogers exercised stock options and sold shares of common stock. On April 1, 2026, he exercised options covering 67,017 shares of common stock at exercise prices of $2.22 and $8.33 per share and received the same number of common shares.
That day, he sold 64,533 shares of common stock at a weighted average price of $24.64 per share in open-market transactions, as part of a Rule 10b5-1 Trading Plan adopted on September 12, 2025. Following these transactions, he holds 81,002 shares directly, along with indirect holdings through several trusts, including 50,754 shares held by The Campbell Rogers Revocable Trust.
HTFL notice of proposed sale under Rule 144 describing planned and recent disposals of Common Stock by named holders and options-related issuances.
The filing lists planned sales tied to prior stock option exercises (12/27/2019: 13,047 shares; 02/17/2021: 3,867 shares; 07/31/2025: 4 shares; 07/10/2023 grant exercised 47,615 shares) and shows actual sales in the past three months by related holders on 02/12/2026 and 03/19/2026 (examples: 16,918 and 47,615 shares with dollar proceeds reported).
Heartflow, Inc. ownership disclosure: HealthCor Partners Management, L.P. reports beneficial ownership of 2,082,014 shares of common stock, representing 2.4% of the class. The filing breaks this down as HealthCor Partners Fund, L.P. 1,248,939 shares (1.5%) and HealthCor Partners Fund II, L.P. 833,075 shares (1.0%). The filing notes a distribution by HCPCIV 1, LLC of 4,615,542 shares on March 24, 2026.
Heartflow, Inc. director Jeffrey C. Lightcap reported an internal restructuring of his share ownership. On March 24, 2026, HCPCIV 1, LLC made a pro rata in-kind distribution of Heartflow common stock to its members, including 206,261 shares allocable to Mr. Lightcap based on his indirect interest. Following this distribution and the dissolution of HCPCIV, these shares are now held directly by Mr. Lightcap, with 246,261 shares shown as directly owned after the transaction. He is also a controlling member of HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P., which report 833,075 and 1,248,939 shares held indirectly, respectively, although he disclaims beneficial ownership beyond his pecuniary interest.
Heartflow, Inc. insider HealthCor Partners Management LP reported a restructuring-type transaction involving 4,615,542 shares of Heartflow common stock. On March 24, 2026, these shares, held indirectly through HCPCIV I, LLC, were distributed to fund investors, and the reporting person’s indirect holdings in this block dropped to zero. This was classified as an “other” transaction rather than an open-market purchase or sale.